SCHEMBL26666503

SCHEMBL26666503

CN(C)c1ccc2[nH]c(=O)n(C)c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.54
▸ ALDH1A1 P00352 4/20 0.51
▸ PGR P06401 2/20 0.51
▸ KDM4E B2RXH2 4/20 0.47
▸ HSD17B10 Q99714 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ MAPT P10636 1/20 0.47
▸ THRB P10828 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ MAOB P27338 3/20 0.46
▸ GAA P10253 3/20 0.45
▸ GLA P06280 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ AR P10275 1/20 0.42
▸ PDE2A O00408 1/20 0.41
▸ PDE3B Q13370 1/20 0.41
▸ PDE3A Q14432 1/20 0.41
▸ BRD4 O60885 2/20 0.41
▸ DAO P14920 1/20 0.41
▸ USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29860748 1.00 LMNA (0.54) LMNAALDH1A1PGRKDM4EHSD17B10
SCHEMBL26666463 0.88 LMNA (0.53) LMNAALDH1A1PGRKDM4EHSD17B10
SCHEMBL9922457 0.78 ADORA3 (0.56) LMNAALDH1A1KDM4EHSD17B10HPGD
SCHEMBL29859942 0.78 LMNA (0.58) LMNAALDH1A1PGRKDM4EMAPT
SCHEMBL7220155 0.78 DAO (0.66) LMNAALDH1A1PGRKDM4EMAPT
SCHEMBL2522765 0.78 LMNA (0.58) LMNAALDH1A1PGRKDM4EMAPT
SCHEMBL11545415 0.77 LMNA (0.42) LMNAALDH1A1PGRHSD17B10MAOB
SCHEMBL3063232 0.76 PGR (0.69) LMNAPGRMAOBDAOADORA3
SCHEMBL1519715 0.76 LMNA (0.56) LMNAPGRHPGDMAPTMAOB
SCHEMBL7220153 0.76 LMNA (0.56) LMNAPGRKDM4EMAOBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150287-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF HANGZHOU APELOA MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) 2024-05-09 — — US disclosed
EP-4282865-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) 2023-11-29 — — EP disclosed
EP-4282865-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Hangzhou Apeloa Medicine Research Institute Co., Ltd. (CN) 2023-11-29 — — EP disclosed
CN-116997550-A N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same and application thereof 杭州普洛药物研究院有限公司 2023-11-03 — — CN disclosed
CN-114853659-A N- (benzoyl) -phenylalanine compounds, pharmaceutical compositions containing same, and uses thereof 普洛药业股份有限公司 2022-08-05 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150287-A1 N-(BENZOYL)-PHENYLALANINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF ITGB7, ITGB4, ITGA4 LMNA 2583/4885ALDH1A1 988/4885PGR 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback